U.S. Markets open in 59 mins.

QIAGEN N.V. (QGEN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
34.57-0.15 (-0.43%)
At close: 4:00PM EDT
People also watch
TECHLMNXLIFEGHDXILMN
Full screen
Previous Close34.72
Open34.76
Bid34.51 x 100
Ask34.57 x 400
Day's Range34.54 - 34.88
52 Week Range21.27 - 35.26
Volume810,466
Avg. Volume833,623
Market Cap7.87B
Beta1.14
PE Ratio (TTM)96.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube5 days ago

    ETFs with exposure to QIAGEN NV : June 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to QIAGEN NV Here are 5 ETFs with the largest exposure to QGEN-US. Comparing the performance and risk of QIAGEN NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • QIAGEN NV :QGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
    Capital Cube11 days ago

    QIAGEN NV :QGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017

    Categories: Yahoo FinanceGet free summary analysis QIAGEN NV reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of QIAGEN NV – Thermo Fisher Scientific Inc., Genomic Health, Inc., Hologic, Inc., Becton, Dickinson and Company, General Electric Company, Trovagene, Inc., Bio-Techne Corporation and GenMark Diagnostics, Inc. (TMO-US, GHDX-US, ... Read more (Read more...)

  • QIAGEN Strengthens Cancer Research Foothold on New License
    Zacks21 days ago

    QIAGEN Strengthens Cancer Research Foothold on New License

    QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.